Clinical Trial Detail

NCT ID NCT02091141
Title My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Genentech
Indications

Advanced Solid Tumor

biliary tract cancer

urinary bladder cancer

salivary gland cancer

Therapies

Erlotinib

Alectinib

Cobimetinib + Vemurafenib

Pertuzumab + Trastuzumab

Vismodegib

Atezolizumab

Age Groups: adult senior

Additional content available in CKB BOOST